Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates

Safety and immunogenicity data from this U.S. phase 1 trial in younger and older adults, added to earlier interim safety and immunogenicity data regarding BNT162b1 in younger adults from trials in Germany and US, support its selection for advancement to phase 2–3 study.

New England Journal of Medicine